Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label odronextamab study in relapsed or refractory B-cell non-Hodgkin lymphoma
jRCT2031210617Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label trial of odronextamab in mature B-cell lymphoma, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and 2 more (5 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Overall response rate in follicular lymphoma grade 1-3a and marginal zone lymphoma and Overall response rate in diffuse large B-cell lymphoma, mantle cell lymphoma, and other B-cell non-Hodgkin lymphoma. Started Jul 2022; status: recruiting.
02
Drugs
odronextamab
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2031210617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210617.